- Home
- RSVR vs PSNL Comparison
RSVR vs PSNL Comparison
Compare RSVR & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RSVR | PSNL |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.9M | 872.1M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | RSVR | PSNL |
|---|---|---|
| Price | $7.62 | $8.97 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $11.50 | $10.71 |
| AVG Volume (30 Days) | 79.3K | ★ 1.6M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $166,320,844.00 | $69,103,000.00 |
| Revenue This Year | $9.06 | N/A |
| Revenue Next Year | $5.37 | $20.33 |
| P/E Ratio | $51.39 | ★ N/A |
| Revenue Growth | ★ 11.17 | N/A |
| 52 Week Low | $6.56 | $2.83 |
| 52 Week High | $9.50 | $11.40 |
Technical Indicators
Market Signals| Indicator | RSVR | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 47.08 |
| Support Level | $7.26 | $9.34 |
| Resistance Level | $7.64 | $9.85 |
| Average True Range (ATR) | 0.18 | 0.70 |
| MACD | 0.03 | -0.15 |
| Stochastic Oscillator | 82.35 | 2.17 |
Price Performance
Historical ComparisonAbout RSVR Reservoir Media Inc.
Reservoir Media Inc is an independent music company. It operates a music publishing business, a recorded music business, a management business, and a rights management entity in the Middle East. The company's segments include Music Publishing and Recorded Music. It generates the maximum of its revenue from the Music Publishing segment.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.